Business Context and Reporting Period
This Form 8-K Current Report was filed by Flotek Industries, Inc. (FTK) on December 6, 2021, with the earliest event reported on that date. The filing addresses a notice of delisting from the New York Stock Exchange (NYSE) and the departure of a senior executive.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data provided relates to executive compensation:
- Dr. James Silas (SVP, Research & Innovation): Annual base salary of $285,000 with a target annual bonus of 100% of base salary.
- Severance Terms: In the event of termination without cause, Dr. Silas is eligible for 12 months of base salary, pro-rata bonus, and COBRA premium subsidies.
Material Changes
Stock Listing Status
The Company received written notice from the NYSE that its common stock's average closing price over 30 consecutive trading days fell below the $1.00 minimum requirement. Consequently, the stock will trade with a ".BC" (below compliance) designation. The Company has six months to cure this deficiency.
Executive Departure
TengBeng Koid, President of Data Analytics, departed the Company on December 9, 2021. The departure is classified as a termination without cause, triggering severance obligations.
Guidance, Outlook, and Risks
Outlook and Remediation: Management intends to notify the NYSE of its intent to cure the listing deficiency and is exploring available options to regain compliance. The stock will continue to trade on the NYSE during the cure period.
Operational Continuity: Dr. James Silas will oversee the Data Analytics division on an interim basis following Mr. Koid's departure.
Risks: The primary risk identified is the potential delisting from the NYSE if the stock price deficiency is not cured within the six-month window.
Investor Verification Checklist
- Verify the current trading price of FTK to assess the likelihood of meeting the $1.00 average closing price requirement within six months.
- Monitor for future filings regarding the specific plan to cure the listing deficiency (e.g., reverse stock split).
- Review the Company's next quarterly or annual report for the financial impact of the severance payments to Mr. Koid.
- Confirm the long-term leadership strategy for the Data Analytics division beyond Dr. Silas's interim role.